サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1757796

多価ワクチンの世界市場

Multivalent Vaccines

出版日
ページ情報
英文 278 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=150.05円
多価ワクチンの世界市場
出版日: 2025年06月27日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 278 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

多価ワクチンの世界市場は2030年までに157億米ドルに到達

2024年に94億米ドルと推定される多価ワクチンの世界市場は、2024～2030年の分析期間にCAGR 9.0％で成長し、2030年には157億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである結合型ワクチンは、CAGR 10.8%を記録し、分析期間終了時には99億米ドルに達すると予測されます。不活化・サブユニットワクチン分野の成長率は、分析期間中CAGR 6.0%と推定されます。

米国市場は26億米ドル、中国はCAGR14.4%で成長予測

米国の多価ワクチン市場は、2024年に26億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに35億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは14.4%です。その他の注目すべき地域別市場としては日本とカナダがあり、分析期間中のCAGRはそれぞれ4.4%と8.7%と予測されています。欧州では、ドイツがCAGR約6.1%で成長すると予測されています。

世界の多価ワクチン市場- 主要動向と促進要因のまとめ

なぜ多価ワクチンは予防接種プログラムの戦略的優先事項なのか？

1つの製剤で複数の病原体株や病原体種を予防する多価ワクチンは、世界の予防接種戦略にとってますます重要となっています。単一の抗原を標的とする一価ワクチンとは異なり、多価ワクチンは広範囲な防御を提供するため、注射の回数を減らし、予防接種スケジュールを簡素化し、患者のコンプライアンスを向上させることができます。このようなワクチンは、小児科、旅行、集団発生など、複数の疾病に対する同時予防が個人にとっても地域社会にとっても重要な状況において、特に有用です。

多価ワクチンの実用的な利点は、利便性にとどまらないです。特に資源に乏しい環境では、ワクチンの保管、輸送、投与における物流コストを削減することができます。公衆衛生当局は、大規模な予防接種キャンペーンに多価ワクチンを使用することで、コンタクトポイントを最小限に抑え、ヘルスケア資源の配分を最適化することができます。新たなウイルスの亜種や共感染の脅威が世界的に出現する中、1回の接種で複数の病原体を予防する能力は、ワクチン開発と展開における中心的な目標になりつつあります。

どのような技術の進歩が多価ワクチンの有効性と構成を向上させているか？

分子生物学、アジュバント技術、タンパク質工学の開発により、より安定で免疫原性が高く、広範囲に予防効果のある多価ワクチンの開発が可能になりつつあります。リコンビナントDNAプラットフォームは、単一のベクターやキャリアーで複数の抗原を発現させることを可能にし、製造効率や抗原適合性を向上させています。サポニン、toll-like receptor agonist、脂質ベースのナノ粒子などの新しいアジュバントは、反応原性を低下させながら免疫応答を増強するために組み込まれています。

さらに、COVID-19ワクチンレースで実証されたように、ウイルスベクターやmRNAプラットフォームは、複数の抗原を単一の構造体でコードできる可能性があるため、研究が進められています。DTP（ジフテリア・破傷風・百日咳）、MMR（麻疹・おたふくかぜ・風疹）などの混合ワクチンや、6価の乳児用ワクチンのような新しい製剤は、予防効果の拡大、忍容性の改善、混合接種スケジュールのサポートなどのために、継続的に改良されています。コールドチェーンの最適化と耐熱性ワクチン製剤は、遠隔地での多価ワクチンの使用可能性も高めています。

多価ワクチンの需要を牽引している疾患と人口層は？

小児用予防接種は、多価ワクチンの最大かつ最も体系的な使用事例であり続けており、乳幼児は1回の注射で最大6つの疾患に対する予防を受けることができます。腸チフス、A型肝炎、B型肝炎、髄膜炎菌感染症などの病気に対する旅行用ワクチンも、世界の旅行者のために頻繁に併用されています。季節性およびパンデミック対策プログラムでは、多価インフルエンザ・ワクチンは、毎年、流行株に合わせて設計され、リスクのある集団に広範な防御を提供します。

高齢者、免疫不全者、ヘルスケア従事者は、特にインフルエンザワクチンとCOVID-19ブースターの併用候補が開発段階に入るにつれて、新世代の多価ワクチンにとって重要なセグメントとなっています。獣医療では、多価ワクチンは家畜やペットを複数のウイルスや細菌感染から守るために広く使用されており、抗菌薬の使用量を減らし、動物の健康状態を改善するのに役立っています。呼吸器合胞体ウイルス（RSV）、COVID-19、インフルエンザ抗原の組み合わせに対する新たな関心が、成体を標的とした多価製品の技術革新を促進しています。

多価ワクチン市場の成長はいくつかの要因によって牽引される...

多価ワクチン市場の成長は、効率的な予防接種スケジュールに対する需要の増加、同時感染症の発生率の上昇、資源が限られた地域でのワクチン入手の容易性を高める必要性など、いくつかの要因によって牽引されています。組換え技術、アジュバント開発、ベクターベースのプラットフォームの開発により、より複雑で安定した多価製剤の設計が可能になってきています。国際保健機関による支援政策、小児・成人ワクチンプログラムへの投資の拡大、パンデミックシナリオにおけるロジスティクスの簡素化の必要性などが、市場導入を加速させています。医療制度が人口カバー率の向上と進化する病原体への対応を目指す中、多価ワクチンは世界の予防接種戦略の最前線であり続けると思われます。

セグメント

タイプ別（結合型ワクチン、不活化ワクチン&サブユニットワクチン、活性化ワクチン）;用途別（小児、成人）

調査対象企業の例（計44社）

  • Abbott Laboratories
  • AstraZeneca plc
  • Bavarian Nordic
  • Bharat Biotech
  • BioNTech SE
  • Boehringer Ingelheim GmbH
  • CSL Seqirus
  • CureVac N.V.
  • Emergent BioSolutions Inc.
  • GC Biopharma Corp.
  • GlaxoSmithKline plc（GSK）
  • Indian Immunologicals Ltd.
  • LimmaTech Biologics AG
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novartis AG
  • Panacea Biotec Ltd.
  • Pfizer Inc.
  • Serum Institute of India Pvt. Ltd.
  • VBI Vaccines Inc.

AIインテグレーション

私たちは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP35400

Global Multivalent Vaccines Market to Reach US$15.7 Billion by 2030

The global market for Multivalent Vaccines estimated at US$9.4 Billion in the year 2024, is expected to reach US$15.7 Billion by 2030, growing at a CAGR of 9.0% over the analysis period 2024-2030. Conjugate Vaccine, one of the segments analyzed in the report, is expected to record a 10.8% CAGR and reach US$9.9 Billion by the end of the analysis period. Growth in the Inactivated & Subunit Vaccine segment is estimated at 6.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.6 Billion While China is Forecast to Grow at 14.4% CAGR

The Multivalent Vaccines market in the U.S. is estimated at US$2.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$3.5 Billion by the year 2030 trailing a CAGR of 14.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.4% and 8.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.1% CAGR.

Global Multivalent Vaccines Market - Key Trends & Drivers Summarized

Why Are Multivalent Vaccines a Strategic Priority in Immunization Programs?

Multivalent vaccines, which protect against multiple strains or species of pathogens in a single formulation, have become increasingly vital to global immunization strategies. Unlike monovalent vaccines that target a single antigen, multivalent formulations offer broad-spectrum protection, thereby reducing the number of injections, simplifying immunization schedules, and improving patient compliance. These vaccines are especially valuable in pediatric, travel, and outbreak-prone contexts where simultaneous protection against several diseases is critical for both individuals and communities.

The practical benefits of multivalent vaccines extend beyond convenience. They reduce logistical costs in vaccine storage, transport, and administration-especially in resource-constrained settings. Public health authorities prefer multivalent solutions for mass immunization campaigns, as they minimize contact points and optimize healthcare resource allocation. As new viral variants and co-infection threats emerge globally, the ability to confer multi-pathogen protection through a single dose is becoming a central objective in vaccine development and deployment.

What Technological Advancements Are Improving the Efficacy and Composition of Multivalent Vaccines?

Advances in molecular biology, adjuvant technology, and protein engineering are enabling the development of more stable, immunogenic, and broadly protective multivalent vaccines. Recombinant DNA platforms allow for the expression of multiple antigens in a single vector or carrier, improving manufacturing efficiency and antigen compatibility. Novel adjuvants such as saponins, toll-like receptor agonists, and lipid-based nanoparticles are being incorporated to enhance immune response while reducing reactogenicity.

Additionally, viral vector and mRNA platforms are being explored for their potential to encode multiple antigens in a single construct, as demonstrated during the COVID-19 vaccine race. Combination vaccines such as DTP (diphtheria-tetanus-pertussis), MMR (measles-mumps-rubella), and newer formulations like hexavalent infant vaccines are being continually refined to extend protection, improve tolerability, and support mixed immunization schedules. Cold chain optimization and thermostable vaccine formulations are also advancing multivalent vaccine usability in remote areas.

Which Diseases and Population Segments Are Driving Demand for Multivalent Vaccines?

Pediatric immunization remains the largest and most structured use case for multivalent vaccines, with infants receiving protection against up to six diseases in a single injection. Travel vaccines for diseases like typhoid, hepatitis A and B, and meningococcal infections are also frequently combined for global travelers. In seasonal and pandemic preparedness programs, multivalent influenza vaccines are designed annually to match circulating strains, providing broad protection in at-risk populations.

Elderly populations, immunocompromised individuals, and healthcare workers are key segments for new generation multivalent vaccines, especially as combination flu and COVID-19 booster candidates enter development. In veterinary medicine, multivalent vaccines are used extensively to protect livestock and pets against multiple viral and bacterial infections, helping reduce antimicrobial use and improve animal health outcomes. Emerging interest in combining respiratory syncytial virus (RSV), COVID-19, and influenza antigens is driving innovation in adult-targeted multivalent products.

The Growth in the Multivalent Vaccines Market Is Driven by Several Factors…

The growth in the multivalent vaccines market is driven by several factors including increasing demand for efficient immunization schedules, rising incidence of co-infections, and the need to enhance vaccine accessibility in resource-limited regions. Advancements in recombinant technology, adjuvant development, and vector-based platforms are enabling the design of more complex yet stable multivalent formulations. Supportive policies by global health organizations, growing investments in pediatric and adult vaccine programs, and the need to simplify logistics in pandemic scenarios are accelerating market adoption. As health systems aim to improve population coverage and respond to evolving pathogens, multivalent vaccines will remain at the forefront of global immunization strategies.

SCOPE OF STUDY:

The report analyzes the Multivalent Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Conjugate Vaccine, Inactivated & Subunit Vaccine, Live Attenuated Vaccine); Application (Pediatrics, Adults)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

  • Abbott Laboratories
  • AstraZeneca plc
  • Bavarian Nordic
  • Bharat Biotech
  • BioNTech SE
  • Boehringer Ingelheim GmbH
  • CSL Seqirus
  • CureVac N.V.
  • Emergent BioSolutions Inc.
  • GC Biopharma Corp.
  • GlaxoSmithKline plc (GSK)
  • Indian Immunologicals Ltd.
  • LimmaTech Biologics AG
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novartis AG
  • Panacea Biotec Ltd.
  • Pfizer Inc.
  • Serum Institute of India Pvt. Ltd.
  • VBI Vaccines Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Multivalent Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Broad-Spectrum Protection Against Infectious Diseases Fuels Development of Multivalent Vaccines
    • OEM Focus on Reducing Doses Per Immunization Cycle Supports Growth in Combined Antigen Formulations
    • Expansion of Pediatric and Routine Immunization Programs Strengthens Use of Multivalent Vaccine Platforms
    • Push for Universal Influenza and Coronavirus Vaccines Accelerates Multivalent Antigen Research
    • Increased Prevalence of Co-Infections Drives Innovation in Multi-Target Vaccine Technologies
    • OEM Development of mRNA-Based Multivalent Vaccines Enhances Speed and Flexibility in Pandemic Response
    • Regulatory Support for Single-Injection Immunization Models Promotes Approval of Combined Vaccine Candidates
    • Growth in Travel and Global Mobility Fuels Demand for Multivalent Protection in Endemic Regions
    • Rising Focus on Elderly and Immunocompromised Populations Strengthens Market for Broad-Protection Vaccines
    • Expansion of Veterinary Multivalent Vaccines Supports Disease Control in Animal Health and Zoonotic Risk
    • Integration of Nanoparticle Carriers and Lipid Formulations Improves Stability and Delivery of Multivalent Vaccines
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Multivalent Vaccines Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Multivalent Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Multivalent Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Multivalent Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Conjugate Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Conjugate Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Conjugate Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Inactivated & Subunit Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Inactivated & Subunit Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Inactivated & Subunit Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Live Attenuated Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Live Attenuated Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Live Attenuated Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Pediatrics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Pediatrics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Pediatrics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Adults by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Adults by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Adults by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Multivalent Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: USA 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: USA 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: Canada 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: Canada 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • JAPAN
    • Multivalent Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Japan 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Japan 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • CHINA
    • Multivalent Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: China 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: China 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • EUROPE
    • Multivalent Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Multivalent Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Multivalent Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Europe 15-Year Perspective for Multivalent Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Europe 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • FRANCE
    • Multivalent Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: France 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: France 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • GERMANY
    • Multivalent Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Germany 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Germany 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Italy 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Italy 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Multivalent Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: UK 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: UK 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Spain 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Spain 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Russia 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Russia 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Multivalent Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Multivalent Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Multivalent Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 15-Year Perspective for Multivalent Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Multivalent Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Australia 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Australia 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • INDIA
    • Multivalent Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 110: India Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: India 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 113: India Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: India 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: South Korea 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: South Korea 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Multivalent Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Multivalent Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Multivalent Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Latin America 15-Year Perspective for Multivalent Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Latin America 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Argentina 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Argentina 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Brazil 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Brazil 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Mexico 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Mexico 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Multivalent Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Multivalent Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Multivalent Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Middle East 15-Year Perspective for Multivalent Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Middle East 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Iran 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Iran 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Israel 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Israel 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: UAE 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: UAE 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • AFRICA
    • Multivalent Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Africa 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Africa 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030

IV. COMPETITION